Read the latest press releases for 4D pharma plc.

Click on a news title to read full details. For Regulatory News Service (RNS) announcements please click here.

Publications
4D pharma Announces Publication of Preclinical Research Showing Live Biotherapeutic MRx0006 Efficacy in Animal Model of Autism Spectrum Disorder
24 Aug 2022, 07:00
4D pharma announces the publication of pre-clinical research relating to its live biotherapeutic…
Presentations
4D pharma Presents Late Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International Conference
17 May 2022, 07:00
4D pharma announces the presentation of a late-breaking poster on data from Part A of the Phase I/II…
4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma
23 Mar 2022, 07:00
Primary Efficacy Endpoint Met Early in Renal Cell Carcinoma Group in Part B of Study. Company to…
4D pharma announces FDA clearance of IND application for Live Biotherapeutics MRx0005 and MRx0029 for the treatment of Parkinson’s disease
22 Feb 2022, 07:00
4D pharma today announces US FDA clearance of its IND applications for Live Biotherapeutics MRx0005…
4D pharma announces additional positive data from Part A of the Phase I/II trial of MRx-4DP0004 for the treatment of asthma
27 Jan 2022, 07:00
Part A of the Phase I/II clinical trial achieved the primary endpoint of safety and tolerability.…
4D pharma appoints John Doyle as Chief Financial Officer
3 Jan 2022, 12:00
4D pharma plc announces the appointment of John Doyle as Chief Financial Officer (CFO). Mr. Doyle…
4D pharma announces positive topline results from Part A of Phase I/II trial of MRx-4DP0004 for the treatment of asthma
13 Dec 2021, 07:00
Part A of the study meets primary endpoint of safety and tolerability MRx-4DP0004 also achieved…
4D pharma presents microbiome analyses from Phase II clinical trial of Blautix® for IBS-C and IBS-D at Gastro 2021
9 Dec 2021, 07:00
Results demonstrate changes in gut microbiome structure following administration of Blautix in both…
4D pharma Announces Two Presentations at European Society for Medical Oncology (ESMO) Congress 2021
2 Aug 2021, 07:00
4D pharma announces two poster presentations at the European Society for Medical Oncology (ESMO)…
4D pharma Announces $30 Million Credit Facility with Oxford Finance
29 Jul 2021, 07:00
4D pharma announces the closing of a senior secured credit facility for up to $30m with Oxford…
4D pharma Announces Passing of Chief Financial Officer John Beck
26 Jul 2021, 13:00
4D pharma announces with great sadness the passing of John Beck, Chief Financial Officer of 4D…
4D pharma Announces Publication of Preclinical Research Showing Single Strain Megasphaera massiliensis improves activity of CAR-T
6 Jul 2021, 07:00
4D pharma (AIM: DDDD, NASDAQ: LBPS) announces the publication of pre-clinical research relating to…
4D pharma to Participate in Ladenburg Thalmann Healthcare Conference
29 Jun 2021, 07:00
4D pharma (AIM: DDDD, NASDAQ: LBPS) management will present a corporate overview followed by a…

BACK TO TOP